IN2014MN01781A - - Google Patents

Download PDF

Info

Publication number
IN2014MN01781A
IN2014MN01781A IN1781MUN2014A IN2014MN01781A IN 2014MN01781 A IN2014MN01781 A IN 2014MN01781A IN 1781MUN2014 A IN1781MUN2014 A IN 1781MUN2014A IN 2014MN01781 A IN2014MN01781 A IN 2014MN01781A
Authority
IN
India
Prior art keywords
cdim
binding proteins
cells
well
diagnostic assays
Prior art date
Application number
Inventor
Nelson N H Teng
Neelirna M Bhat
Marcia M Bieber
Bruce A Keyt
Original Assignee
Igm Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igm Biosciences Inc filed Critical Igm Biosciences Inc
Publication of IN2014MN01781A publication Critical patent/IN2014MN01781A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present disclosure relates to Cell Death Inducing Molecule ('CDIM') binding proteins and pharmaceutical compositions thereof. Particularly the disclosure provides CDIM binding proteins that are useful in the selective depleting and killing of B cells including neoplastic B cells as well as neoplastic cells that are not of B cell origin that express CDIM like antigens. In addition the disclosure encompasses polynucleotides encoding the disclosed antigen binding proteins and expression systems for producing the same. Further the present disclosure encompasses methods of treating patients with B cell proliferative and mediated diseases by administering the CDIM binding proteins as well as diagnostic assays for identifying proteins that bind to CDIM. The disclosure further contemplates diagnostic assays for identifying patient populations that can be treated with the CDIM binding proteins.
IN1781MUN2014 2012-02-08 2013-02-08 IN2014MN01781A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261633330P 2012-02-08 2012-02-08
PCT/US2013/025430 WO2013120012A2 (en) 2012-02-08 2013-02-08 Cdim binding proteins and uses thereof

Publications (1)

Publication Number Publication Date
IN2014MN01781A true IN2014MN01781A (en) 2015-07-03

Family

ID=48045015

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1781MUN2014 IN2014MN01781A (en) 2012-02-08 2013-02-08

Country Status (14)

Country Link
US (1) US9409976B2 (en)
EP (1) EP2812356B1 (en)
JP (1) JP6335796B2 (en)
KR (1) KR102102111B1 (en)
CN (1) CN104254544B (en)
AU (1) AU2013200903B2 (en)
BR (1) BR112014019459B1 (en)
CA (1) CA2863714C (en)
DK (1) DK2812356T3 (en)
ES (1) ES2735289T3 (en)
IN (1) IN2014MN01781A (en)
MX (1) MX363819B (en)
TW (1) TWI606064B (en)
WO (1) WO2013120012A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3041862T3 (en) 2013-09-05 2020-07-27 Igm Biosciences Inc MODIFIED BISPECIFIC, PENTA AND HEXAVALENT IG-M ANTIBODIES WITH CONSTANT CHAIN
KR20240042192A (en) 2013-12-17 2024-04-01 크링 바이오테라퓨틱스 비.브이. Means and methods for counteracting myeloproliferative or lymphoproliferative disorders
DK3105250T3 (en) 2014-02-10 2020-09-28 Igm Biosciences Inc MULTISPECIFIC IGA BINDING MOLECULES
IL292311A (en) 2014-04-03 2022-06-01 Igm Biosciences Inc Modified j-chain
JP7179464B2 (en) 2015-01-20 2022-11-29 アイジーエム バイオサイエンシズ インコーポレイテッド Tumor necrosis factor (TNF) superfamily receptor-binding molecules and their uses
SG11201707144VA (en) * 2015-03-04 2017-09-28 Igm Biosciences Inc Cd20 binding molecules and uses thereof
AU2016238246B2 (en) 2015-03-25 2021-05-13 Igm Biosciences, Inc. Multi-valent hepatitis B virus antigen binding molecules and uses thereof
JP6811723B2 (en) 2015-04-17 2021-01-13 アイジーエム バイオサイエンシズ インコーポレイテッド Multivalent human immunodeficiency virus antigen-binding molecule and its usage
US11639389B2 (en) 2015-09-30 2023-05-02 Igm Biosciences, Inc. Binding molecules with modified J-chain
CA2999284C (en) 2015-09-30 2023-06-13 Igm Biosciences A/S Binding molecules with modified j-chain
DK3455257T3 (en) 2016-05-09 2021-11-01 Igm Biosciences Inc ANTI-PD-L1 ANTIBODIES
RS64541B1 (en) 2016-08-15 2023-09-29 Novartis Ag Regimens and methods of treating multiple sclerosis using ofatumumab
US20200095327A1 (en) * 2017-02-08 2020-03-26 Dragonfly Therapeutics, Inc. Antibody heavy chain variable domains targeting the nkg2d receptor
DK3579848T3 (en) 2017-02-08 2025-01-20 Dragonfly Therapeutics Inc MULTISPECIFIC BINDING PROTEINS FOR ACTIVATING NATURAL KILLER CELLS AND THERAPEUTIC APPLICATIONS THEREOF FOR THE TREATMENT OF CANCER
KR20240060739A (en) 2017-02-20 2024-05-08 드래곤플라이 쎄라퓨틱스, 인크. Proteins binding her2, nkg2d and cd16
KR102696143B1 (en) 2017-04-07 2024-08-21 아이쥐엠 바이오사이언스 인코포레이티드 Modified human IgM constant region for modulation of complement-dependent cytolytic effector function
SG11202007482WA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Antibody variable domains targeting the nkg2d receptor
SG11202007579TA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
JP7353576B2 (en) 2018-02-20 2023-10-02 ドラゴンフライ セラピューティクス， インコーポレイテッド Multispecific binding proteins that bind to CD33, NKG2D, and CD16, and methods of use thereof
EP3758752A4 (en) 2018-03-01 2021-12-15 IGM Biosciences Inc. IGM CF AND J-CHAIN MUTATIONS THAT AFFECT IGM SERIAL HALF-LIFE
EP3833392A4 (en) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. MULTI-SPECIFIC BINDING PROTEINS BINDING TO BCMA, NKG2D AND CD16, AND METHODS OF USE
EP3833385A4 (en) 2018-08-08 2021-12-22 Dragonfly Therapeutics, Inc. NKG2D, CD16 AND TUMOR-ASSOCIATED ANTIGEN BINDING PROTEINS
EA202091888A1 (en) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. VARIABLE ANTIBODY DOMAINS TARGETED ON THE NKG2D RECEPTOR
JP7627216B2 (en) * 2018-11-16 2025-02-05 メモリアル スローン ケタリング キャンサー センター Antibodies to mucin-16 and methods of using same - Patents.com
AU2020329301A1 (en) 2019-08-15 2022-02-17 Igm Biosciences, Inc. Immunostimulatory multimeric binding molecules
CN115836088A (en) 2020-05-06 2023-03-21 蜻蜓疗法股份有限公司 Proteins that bind NKG2D, CD16, and CLEC12A
JP2024500847A (en) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド Chimeric antigen receptor systems with compatible receptor specificities
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
CN114181318B (en) * 2021-11-08 2023-08-01 四川大学 Recombinant adeno-associated virus for tissue-specific expression of IDUA fusion protein penetrating blood brain barrier and application thereof
CN116041489A (en) * 2022-09-27 2023-05-02 丹娜(天津)生物科技股份有限公司 Monkeypox virus binding protein and its application, monkeypox virus detection kit

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5246692A (en) 1986-09-05 1993-09-21 The United States Of America As Represented By The Secretary Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5099069A (en) 1986-09-05 1992-03-24 Gansow Otto A Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
DE3920358A1 (en) * 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US5124471A (en) 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
DE69233528T2 (en) 1991-11-25 2006-03-16 Enzon, Inc. Process for the preparation of multivalent antigen-binding proteins
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5417972A (en) 1993-08-02 1995-05-23 The Board Of Trustees Of The Leland Stanford Junior University Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6312691B1 (en) 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US6962979B1 (en) 1995-03-14 2005-11-08 Cohesion Technologies, Inc. Crosslinkable biomaterial compositions containing hydrophobic and hydrophilic crosslinking agents
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6680335B2 (en) 1998-09-28 2004-01-20 Sugen, Inc. Methods of modulating protein tyrosine kinase function with substituted indolinone compounds
KR20020088406A (en) 1999-09-17 2002-11-27 애보트 게엠베하 운트 콤파니 카게 Pyrazolopyrimidines as therapeutic agents
US20020028178A1 (en) 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
EP1485075A4 (en) * 2002-02-20 2006-04-26 Dyax Corp Mhc-peptide complex binding ligands
US7485297B2 (en) * 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
US20120237441A9 (en) * 2003-11-05 2012-09-20 Bhat Neelima M Enhanced b cell cytotoxicity of cdim binding antibody
CN1878568A (en) 2003-11-05 2006-12-13 盘林京有限公司 Enhanced B cell cytotoxicity of CDIM binding antibody
CA2586285A1 (en) * 2004-11-05 2006-05-18 Palingen, Inc. Antibody induced cell membrane wounding
DE602005027258D1 (en) * 2005-03-14 2011-05-12 Us Gov Health & Human Serv HUMAN MONOCLONAL ANTIBODIES TO HENDRA AND NIPAH VIRUSES
JP2009508964A (en) * 2005-09-19 2009-03-05 パリンゲン インコーポレーテッド Treatment of B-cell disease using anti-germline antibody binders
PA8775101A1 (en) * 2007-04-02 2008-11-19 Pfizer ANTI-IGE ANTIBODIES

Also Published As

Publication number Publication date
BR112014019459A8 (en) 2023-01-10
CN104254544A (en) 2014-12-31
JP6335796B2 (en) 2018-06-06
TW201345921A (en) 2013-11-16
BR112014019459A2 (en) 2017-06-27
EP2812356A2 (en) 2014-12-17
MX2014009628A (en) 2015-03-19
MX363819B (en) 2019-04-03
DK2812356T3 (en) 2019-07-08
KR20150001728A (en) 2015-01-06
WO2013120012A2 (en) 2013-08-15
CA2863714C (en) 2022-07-05
JP2015511817A (en) 2015-04-23
CA2863714A1 (en) 2013-08-15
WO2013120012A3 (en) 2013-11-07
BR112014019459B1 (en) 2023-04-18
AU2013200903B2 (en) 2015-05-14
ES2735289T3 (en) 2019-12-17
US20140044739A1 (en) 2014-02-13
EP2812356B1 (en) 2019-03-27
AU2013200903A1 (en) 2013-08-22
HK1205136A1 (en) 2015-12-11
KR102102111B1 (en) 2020-04-20
TWI606064B (en) 2017-11-21
US9409976B2 (en) 2016-08-09
CN104254544B (en) 2017-04-26

Similar Documents

Publication Publication Date Title
MX2014009628A (en) Cdim binding proteins and uses thereof.
PH12019500441A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
MX349096B (en) Anti-pd-l1 antibodies and uses thereof.
PH12018500640A1 (en) Optimized monoclonal antibodies agaist tissue factor pathway inhibitor (tfpi)
UA118332C2 (en) Cs27l antigen binding proteins
PH12015501092A1 (en) Anti-ceacam5 antibodies and uses thereof
PH12017501583B1 (en) Novel proteins specific for cd137
BR112013019975A2 (en) "Antigen binding proteins, pharmaceutical composition, use of an antigen binding protein, method for treating a patient and method for preparing an antigen binding protein, nucleic acid, vector and host cell"
MY177970A (en) Bcma (cd269/tnfrsf17) -binding proteins
BR112014029099A2 (en) anti-egfr antibodies and their use to inhibit or attenuate tumor growth, as well as a pharmaceutical composition comprising
IN2014CN03936A (en)
PH12015500084A1 (en) Rspo3 binding agents and uses thereof
MY156286A (en) Human il-23 antigen binding proteins
PH12013502118A1 (en) Aryl-or heteroaryl-substituted benzene compounds
GB201201314D0 (en) Composition
NZ702457A (en) Anti-fcrn antibodies
PH12020550598A1 (en) Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells
NZ701370A (en) Il-6 binding molecules
EA201370155A1 (en) COMPOSITION AND METHOD OF TREATMENT OF CANCER
BR112012014345A2 (en) tmem22 peptides and vaccines including the same
WO2013040547A3 (en) Compounds and methods of immunization with tumor antigens